Capricor Therapeutics is suing its Japanese partner Nippon Shinyaku over alleged mismanagement in launching its Duchenne muscular dystrophy therapy, deramiocel, claiming that the partner's actions could hinder patient access due to a problematic pricing structure. Additionally, there are concerns about the decline in scientific creativity with age, as highlighted by recent studies.
The most valuable insight for someone tracking healthtech and biotech is the ongoing legal battle between Capricor Therapeutics and Nippon Shinyaku over the launch of a Duchenne muscular dystrophy cell therapy. This situation highlights the critical importance of strategic partnerships and pricing strategies in ensuring accessibility and successful commercialization of innovative therapies, which could have implications for investment and collaboration decisions in the biotech sector.